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Abstract
The nucleoside analogue Ribavirin significantly increases patient response to IFN-a treatment of HCV, by directly inhibiting
viral replication. Recent studies indicate that Ribavirin also regulates immunity and we propose that Ribavirin enhances
specific interferon sensitive gene (ISG) expression by amplifying the IFN-a-JAK/STAT pathway. We found that IFN-a-induced
STAT1 and STAT3 phosphorylation was increased in hepatocytes co-treated with Ribavirin and IFN-a, compared to IFN-a
alone. Ribavirin specifically enhanced IFN-a induced mRNA and protein of the anti-viral mediator MxA, which co-localised
with HCV core protein. These novel findings indicate for the first time that Ribavirin, in addition to its viral incorporation,
also enhances IFN-a-JAK/STAT signalling, leading to a novel MxA-mediated immuno-modulatory mechanism that may
enhance IFN-a anti-viral activity against HCV.
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Introduction
In combination with the anti-viral cytokine interferon (IFN)-a,
Ribavirin is used to treat chronic Hepatitis C Virus (HCV) infection.
Ribavirin lowers serum alanine aminotransferase levels of HCV
infected patients [1], reduces HCV RNA levels [2,3], decreases
patient relapse and more than doubles the sustained virological
response (SVR) obtained with IFN-a monotherapy [4–6]. Ribavirin
(1-b-D-ribofuranosyl-1, 2, 4-triazole-3-carboxamide) is a synthetic
guanosine nucleoside analogue, that directly inhibits viral replication
by depleting guanosine pools upon inhibition of inosine monophos-
phate dehydrogenase [7], inhibiting HCV non-structural-5B poly-
merase [8] and incorporating into the viral genome, leading to error
catastrophe [9]. However, in addition to its effect on viral replication,
this nucleoside analogue is also thought to have immune modulatory
properties, including the regulation of macrophage and T helper (Th)
cell produced cytokines, modulation of the Th1/Th2 subset balance
and the enhancement of IFN sensitive gene (ISG) expression,
suggesting an effect on the JAK/STAT pathway [10–15].
Anti-viral responses to IFN-a are mediated by a number of key
proteins induced through activation of the JAK/STAT pathway,
including double-stranded RNA-activated protein kinase (PKR)
and 2959-oligoadenylate synthethase (2959-OAS), which block
translation and degrade viral RNA, respectively. A third critical
anti-viral protein is a dynamin-like large guanosine triphosphatase
(GTPase), myxovirus resistance gene A (MxA), which is upregulated
by IFN-a in many species [16]. Mx proteins were initially
discovered in influenza A resistant mice and are thought to mediate
innate immunity against numerous RNA viruses, including
Hepatitis B [17,18]. Human Mx proteins (MxA and MxB) are
cytoplasmic and involved in vesicle trafficking via their association
with the cytoskeleton and endoplasmic reticulum. In fact, this
interaction is thought to mediate anti-viral activity by complexing
withviralnucleocaspids and traffickingthem to cellular locationsfor
isolation or degradation [19–21]. This effective anti-viral mecha-
nism is clearly demonstrated in MxA over-expressing mice, which
lack functional IFNa/b receptors, but survive normally lethal viral
infections despite the inability to mount IFN responses [22].
Since Ribavirin mono-therapy does not clear HCV infection, but
enhancespatientresponsetoIFN-a,animmuno-modulatoryeffectis
likely, but remains poorly understood. Therefore, the aim of this
study was to examine the effect of Ribavirin on IFN-a intracellular
signalling, in a bid to further elucidate its mechanism of action. We
found that Ribavirin enhanced IFN-a-induced phosphorylation of
STAT1 and STAT3 and MxA expression in Huh7 hepatocytes,
revealing a novel mechanism of immune regulation by Ribavirin.
Furthermore, HCV core protein co-localised with and enhanced
MxA protein, implicating MxA as an important anti-viral mediator
against HCV. These results are the first to provide a novel insight
into the immune modulatory mechanism used by Ribavirin to
enhance patient response to IFN-a and may reveal targets within the
JAK/STAT pathway for enhancement of current therapy for HCV.
Methods
Cell culture
Huh7 cells were grown in 10% FCS, 250 U/ml penicillin,
250 mg/ml streptomycin and 6 mg/ml zeocin DMEM.
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RNA was isolated from cells following the Trizol manufacturer’s
protocol and cDNA was synthesised using Omniscript (Invitrogen,
USA). Each reaction was duplicated, with a total volume of 25 ml:
2 ml of cDNA (40 ng/ml), 12.5 ml Sybr green PCR master mix
(Roche, Switzerland) and 10.5 ml primer/H2O. qRT-PCR was
performed using a MX3000PH system (Stratagene Corp, USA), at
95uC for 30 sec, 60uC for 1 min and 72uC for 30 sec. Gene
amplifications were normalised to Ribosomal protein 15 (RPS15).
Data analysis was carried out using the 2
2DDCT method [23].
Livak and Schmittgen, 2001).
Primers:
MxA-F-GGTGGTGGTCCCCAGTAATG
MxA-R-ACCACGTCCACAACCTTGTCT
PKR-F-TCTCAGCAGATACATCAGAGATAAATTCT
PKR-R-AGTATACTTTGTTTCTTTCATGTCAGGAA
2959-OAS-F-AAGAGCCTCATCCGCCTAGTC
2959-OAS-R-AAATCCCTGGGCTGTGTTGA
CXCL10-F-CCAATTTTGTCCACGTGTTGAG
CXCL10-R-GCTCCCCTCTGGTTTTAAGGA
RPS15-F-CGGACCAAAGCGATCTCTTC
RPS15-R-CGCACTGTACAGCTGCATCA
Transfection
Huh7 cells expressing T7 polymerase were transfected for 12 h
using Lipofectamine2000 (Invitrogen, USA), with 5 mgo fT 7
driven, non-replicating pBRTM/HCV1-3011 DNA construct,
containing the entire HCV open reading frame, but lacking the 39
and 59 untranslated regions or EV (Invitrogen, USA) in 9 cm
plates or with 0.1 mg in poly-D-lysine slides (Becton Dickson, USA)
[24].
Immunoprecipitation and immunoblotting
Huh7 cells were transfected with EV/HCV for 12 h, rested for
2 h in 2% FCS DMEM and then treated with IFN-a (1000 U/ml)
and Ribavirin (10 mM). Cells were harvested in lysis buffer
(50 mM Hepes, 100 mM NaCl, 1 mM EDTA, 10% glycerol,
0.5% NP40, aprotinin [5 mg/ml], leupeptin [5 mg/ml], PMSF
[1 mM] and Na3VO4 [1 mM]). Protein levels of whole cell lysate
were measured using a bicinchoninic acid protein assay (Thermo
Scientific) and equal amounts of protein were resolved in SDS-
PAGE, followed by transferring to nitrocellulose or polyvinylidene
difluoride membranes (Millipore) and blotting with either
pSTAT1 (Y701) or pSTAT3 (Y705) (Cell signal), re-blocked and
probed for either STAT1 (Cell signal, USA) or STAT3 (Santa
Cruz Biotechnologies, USA) and B-actin (Sigma, USA). Blots were
stripped of antibody between probing using stripping buffer
(Millipore, USA). Lysates were also immunoprecipitated with
protein-A/G agarose beads and MxA antibody (Santa Cruz
Biotechnologies, USA), before immunoblotting for MxA. Whole
cell lysates were probed for HCV core (Abcam, UK) and b-actin
(Sigma, USA). Infrared dye-labelled secondary antibodies were
used for detection (Li-Cor). Proteins were analysed on an Odyssey
Infrared Imaging system using near-infrared fluorescence detec-
tion (Li-Cor).
Immunofluorescence
Huh7 cells were seeded on poly-D-lysine slides for 12 h, before
HCV transfection. Cells were fixed for 30 min on ice with 4%
paraformaldehyde, washed X3 in PBS and permeabilised using
0.2% Triton x-100 (Sigma, USA) for 15 min at room temperature
(RT). Washed X3 in PBS and blocked with PBS containing 4%
BSA for 1 h at RT, then incubated with primary antibody in PBS
containing 4% BSA overnight at 4 ˚C, followed by incubation with
the secondary antibody in 4% BSA for 1 h at RT. Washed X3
with PBS. The slides were mounted using Prolong gold anti-fade
reagent containing DAPI (Invitrogen, USA). MxA (Santa Cruz
Biotechnologies, USA) was detected using an Alexa 488-
conjugated anti-goat antibody (Invitrogen, USA) HCV core
(Abcam, USA) was detected using an Alexa 568-conjugated anti-
mouse antibody.. Microscopy was performed on an Olympus
FV1000 laser scanning confocal microscope, using an UPlan-
SAPO 60X/1.35 NA oil objective. Cells were digitally sectioned at
0.3 mm per slice and analyzed using the Olympus software.
Statistical analysis
Data are represented as bar graphs, created from the raw data
in Excel or Prism. Groups were then compared using Student’s T-
test for statistical significance.
Results
Ribavirin/IFN-a co-treatment increases STAT activation
Since the addition of Ribavirin to IFN-a treatment greatly
increases HCV clearance, we wondered if Ribavirin enhances
IFN-a-mediated JAK/STAT signal transduction. Initially, we
treated Huh7 cells with Ribavirin for 2 and 4 h alone; IFN-a for
15 min alone and Ribavirin pretreatment for 2 and 4 h, before
15 min IFN-a. Lysates were analysed for pSTAT1, STAT1,
pSTAT3 and STAT3 protein expression by immunoblotting. As
expected, STAT1 and STAT3 phosphorylation occurred after the
addition of IFN-a for 15 min. While stimulation with Ribavirin
alone did not induce phosphorylation of STAT1 or STAT3,
Ribavirin pretreatment amplified subsequent IFN-a-induced
STAT1 and STAT3 phosphorylation (Fig. 1). This data
demonstrates that Ribavirin enhances IFN-a signal transduction
in hepatocytes, which may reveal a mechanism by which Ribavirin
increases response to IFN-a therapy in HCV-infected patients.
Ribavirin specifically enhances induction of MxA mRNA
and protein
Having observed that Ribavirin increased IFN-a-mediated
STAT1 and STAT3 phosphorylation, we subsequently analysed
the induction of downstream anti-viral ISGs, including PKR, OAS
Figure 1. IFN-a induced STAT1 and STAT3 phosphorylation is
enhanced in the presence of Ribavirin. Lysates from Huh7
hepatocytes treated with IFN-a for 2 h, Ribavirin for 2 h or both for
2 h were immunoblotted for pSTAT1 and 3 and reprobed for their
protein counterparts and b-actin loading control (data representative of
three independent experiments).
doi:10.1371/journal.pone.0027866.g001
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Ribavirin separately and together for 2 h, before analysing PKR,
2959-OAS and MxA mRNA expression by qRT-PCR. To further
determine Ribavirin’s functional specificity, mRNA levels of the
chemokine CXCL10 were measured as a control, since it is
strongly upregulated in response to IFN-a, but does not exhibit
direct anti-viral activity like PKR, 2959-OAS and MxA [25]. IFN-
a stimulation strongly induced ISG mRNA expression, while
Ribavirin alone had little effect on gene levels. The addition of
Ribavirin alongside IFN-a led to a reduction in PKR, 2959-OAS
and CXCL10 mRNA. However, MxA message was potentiated
by Ribavirin/IFN-a co-stimulation (Fig. 2). These results indicate
that Ribavirin specifically enhances IFN-a induction of MxA
mRNA, via increased STAT phosphorylation, revealing a novel
insight into how these therapeutics increase anti-viral responses.
Since we found that a combination of Ribavirin and IFN-a
increased MxA mRNA, we wondered whether protein levels were
also affected. Therefore, we treated Huh7 cells with IFN-a and
Ribavirin separately and together for 2 h, before lysates were
harvested, immunoprecipitated for MxA and analysed by Western
blotting. While MxA protein was constitutively present in Huh7 s,
the addition of IFN-a or Ribavirin alone had no significant impact
after 2 h. However, Ribavirin/IFN-a co-treatment mirrored the
previously observed mRNA expression by increasing MxA protein
levels (Fig. 3A). To further explore the effect of Ribavirin and IFN-
a upon MxA protein expression, we treated Huh7 hepatocytes
with IFN-a and Ribavirin as before and analysed MxA protein
expression by confocal microscopy. We found that Ribavirin and
IFN-a together visually increased cytoplasmic MxA protein levels
(Fig. 3B), providing support for the MxA protein upregulation
observed by immunoblotting (Fig. 3A). These findings indicate
that the addition of Ribavirin to IFN-a treatment elevates
hepatocyte MxA expression, which may have functional anti-viral
consequences during treatment for HCV infection.
HCV core protein co-localises with MxA
Since these results suggest that MxA is an important anti-viral
protein during IFN-a/Ribavirin combination treatment and MxA
is thought to bind viral core proteins, targeting them for
endosomal isolation, we wondered if MxA also associated with
HCV in this manner. Therefore, we initially transfected Huh7
hepatocytes with the non-replicating pBRTM/HCV1-3011 DNA
construct over a 24 h time course to determine the optimal
transfection time for HCV core protein expression. We found that
HCV core protein was strongly expressed within 12 h (Fig. 4A).
Next, we transfected Huh7 hepatocytes with a HCV-DNA
construct for 12 h and using confocal microscopy, we analysed
the association of MxA with HCV. MxA protein levels were
increased upon expression of HCV proteins via the transfection of
the HCV-DNA construct, indicating a direct MxA-mediated anti-
viral response to HCV protein expression. Furthermore, MxA co-
localised in a cytoplasmic granular pattern with HCV core
(Fig. 4A). We also found that MxA co-localisation with HCV
appeared more aggregated, rather than diffuse, upon co-treatment
with Ribavirin and IFN-a. (Fig. 4C), suggesting that Ribavirin
increases IFN-a-induced MxA expression, thus promoting direc-
tional localisation with HCV. These results indicate that MxA
targets HCV and suggest that IFN-a/Ribavirin co-treatment may
enhance this novel anti-viral process.
Discussion
Ribavirin increases the response rate of HCV-infected patients
to IFN-a therapy, through mechanisms that remain largely
Figure 2. Ribavirin treatment specifically enhances IFN-a-
induced MxA mRNA. Quantitative RT-PCR analysis of Huh7 cells
treated with IFN-a alone for 2 h, Ribavirin alone for 2 h and RBV and
IFN-a together for 2 h. Stimulated values are relative to untreated
which are normalized to one (n=4).
doi:10.1371/journal.pone.0027866.g002
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the nucleosides adenosine and guanosine. We found that Ribavirin
amplified IFN-a-induced STAT1 and STAT3 phosphorylation
and that this combined treatment also increased MxA expression,
but had no effect on PKR or 2959-OAS, indicating that Ribavirin
amplification of JAK/STAT signalling specifically enhances the
anti-viral protein MxA. Ribavirin has been shown to upregulate
IFN-a receptor expression of hepatocytes [12], perhaps providing
a mechanism for our observed increase in IFN-a signal
transduction and MxA expression. Interestingly, we observed that
in hepatocytes transfected with an HCV-DNA construct, MxA
and HCV core protein co-localised in a granular pattern, which
may resemble vacuole or endosomal encasement. These findings
outline a mechanism by which Ribavirin may enhance anti-viral
responses to IFN-a, and suggest that MxA may be fundamental in
Figure 3. MxA protein expression is enhanced with the
addition of IFN-a and Ribavirin. (A) Immunoblot of lysates
immunoprecipitated for MxA and probed for MxA from Huh7s treated
with IFN-a for 2 h, Ribavirin for 2 h or both for 2 h (n=3). (B) Confocal
micrograph of Huh7s treated with IFN-a for 2 h, Ribavirin for 2 h or
both for 2 h (n=3). Confocal micrograph shows MxA and the nucleus,
labelled with Alexa 488 and DAPI, respectively. Bar, 10 mm.
doi:10.1371/journal.pone.0027866.g003
Figure 4. HCV core co-localises with MxA. (A) Immunoblot of
lysates from Huh7 cells transfected with HCV-DNA construct for 0, 6, 12
and 24 h, probed with HCV core and b-Actin (n=3). (B) Confocal
micrograph of Huh7s transfected with EV or HCV-DNA construct (n=3).
(C) Huh7s transfected with HCV-DNA construct and treated with IFN-a
for 2 h, Ribavirin for 2 h or both for 2 h (n=4). Confocal micrographs
show MxA, HCV core and the nucleus, labelled with Alexa 488, Alexa
568 and DAPI, respectively. Antibody staining is indicated along the
side of images Bar, 10 mm (n=3).
doi:10.1371/journal.pone.0027866.g004
Ribavirin Enhances the IFN-a JAK/STAT Pathway
PLoS ONE | www.plosone.org 4 November 2011 | Volume 6 | Issue 11 | e27866targeting HCV, thus explaining improved response of patients
given Ribavirin in combination with IFN-a.
In agreement with a previous study of chronic HCV infected
human livers [26], we found that the presence of HCV increased
MxA expression in hepatocytes, suggesting that HCV acts either
directly or via paracrine/autocrine induction of IFN-a to induce
MxA. Even though MxA has been shown to block the replication
of RNA viruses, its exact effect on HCV is undetermined. Frese et
al., found that the HCV replicon was not affected by over-
expression of MxA and dominant negative MxA did not block
IFN-a responses [27]. However, this study did not include
Ribavirin; which, as our results suggest, is required for enhanced
IFN-a signalling and MxA expression. Furthermore, MxA acts by
targeting viruses to endosomal compartments for isolation or
degradation, a process that may not lower observed levels of
cellular HCV in vitro [16]. Indeed, our results show a granular
pattern of HCV core:MxA in Huh7 cells, possibly demonstrating
this anti-viral mechanism in action. In contrast, Thomas et al.,
found that IFN-a and Ribavirin inhibit cell cultured HCV
infection of Huh7 cells and Itsui et al., found that over-expression
of ISGs, including MxA, significantly suppressed the HCV
replicon, demonstrating MxA’s anti-viral activity against HCV
[13,28].
With the imminent introduction of new protease inhibitors for
the treatment of HCV, it was initially thought that IFN-a and
Ribavirin might become redundant. However, the phase 2 study
for Telaprevir showed that a group of HCV-infected patients
given Telaprevir and IFN-a for 12 weeks had SVR of 36%,
compared to 60% SVR of those who received Telaprevir, IFN-a
plus Ribavirin [29]. These data indicate that Ribavirin will
continue to be critical for improved patient response in these novel
combination therapies. Together with our results, this suggests that
the anti-viral action of protease inhibitors against HCV may
further increase the positive effects of Ribavirin upon IFN-a
signalling, generating a high level of SVR.
In conclusion, we show that Ribavirin enhances IFN-a JAK/
STAT signalling and have identified MxA as a key component of
this anti-viral response, which is important in our understanding of
how these therapeutics function and in the development of
tailored, effective therapeutic care for HCV-infected patients.
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